Filter by
-
UMB Dataset
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
- Authors
- Joseph FraimanJuan ErvitiMark JonesSander Greenland3 more author(s)...
- Description
An adapted version of the Brighton Collaboration priority list was used to evaluate serious adverse events (SAE) of special interest observed in mRNA Covid-19 vaccine trials. In December of 2020, reviewers searched journal publications and trial data on the FDA’s and Health Canada’s websites to locate SAE results tables for these trials. For each trial, blinded SAE tables were prepared. Using these...
- Subject
-
COVID-19/prevention & controlVaccines
- Timeframe
- 2020
- Access Rights
- Unrestricted access
-
UMB Dataset
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
- Authors
- Etsuro NanishiMarisa E. McGrathTimothy R. O’MearaSoumik Barman17 more author(s)...
- Description
This study investigates multiple vaccine strategies to enhance immunogenicity and protection against SARS-CoV-2 in aged mice. The study aims to determine the effect of a booster dose, with an emphasis on older age. Female three and eleven-month-old BALB/c mice were studied over the course of 38 weeks. Mice received BNT162b2 SARS-CoV-2 spike mRNA vaccine series, primary vaccination series, and mock...
- Subject
-
COVID-19/prevention & controlViral Vaccines/genetics
- Access Rights
- Unrestricted access
- Local Experts
- Matthew B. Frieman
-
UMB Dataset
Evaluation of COVID-19 vaccination strategies with a delayed second dose
- Authors
- Seyed M. MoghadasThomas N. VilchesKevin ZhangShokoofeh Nourbakhsh3 more author(s)...
- Description
Due to constraints in vaccine supply, this agent-based model of COVID-19 transmission was developed to compare the impact of two vaccination strategies: 1) vaccinate more individuals with the first dose of available vaccines and delay the second dose or 2) to continue with the recommended 2-dose series as tested in clinical trials. Model population was stratified into 6 age groups of 0 to 4, 5 to 19,...
- Subject
-
COVID-19 Vaccines/administration & dosageCOVID-19/prevention & controlSARS-CoV-2/immunology
- Access Rights
- Unrestricted access
- Local Experts
- Meagan C. Fitzpatrick